OS according to sample time and mutation number. OS in patients grouped by final disease category from time of (A) prediagnostic sample and (B) diagnostic sample. The survival of the AML group is comparable to the RAEB group if determined from the prediagnostic sample (P = .442) and highlights a potential period for earlier intervention. (C) OS according to the number of mutations detected in a prediagnostic sample grouped into those with ≤3 and >3 mutations.